
CLAIMS:

1. A compound of formula (I)



(**I**)

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,

wherein

R^1 and R^2 are each independently hydrogen, halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^a, -SO_2R^a, -COR^a, -CO_2R^a, -$CONR^aR^b$, -C (=NR^a)NR^bR^c, -NR^aR^b, -NR^aCOR^b, -$NR^aCONR^bR^c$, -$NR^aCO_2R^b$, -$NR^aSONR^bR^c$, -$NR^aSO_2NR^bR^c$, or –$NR^aSO_2R^b$, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy, -C_{1-8}alkyoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^a, R^b, and R^c are each independently hydrogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

n is 0, 1, 2, 3 or 4;

R^3 and R^4, at each of its occurrence, are independently halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, -C_{1-8}alkyl-heterocyclyl, -C_{1-8}alkyl-cycloalkyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{3a}, -SO_2R^{3a}, -$SO_2NR^{3a}R^{3b}$, -COR^{3a}, -CO_2R^{3a}, -$CONR^{3a}R^{3b}$, -C (=NR^{3a})$NR^{3b}R^{3c}$, -$NR^{3a}R^{3b}$, -$NR^{3a}COR^{3b}$, -$NR^{3a}CONR^{3b}R^{3c}$, -$NR^{3a}CO_2R^{3b}$, -$NR^{3a}SONR^{3b}R^{3c}$, -$NR^{3a}SO_2NR^{3b}R^{3c}$, or –$NR^{3a}SO_2R^{3b}$, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, -C_{1-8}alkyl-heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{3d}; or R^3 and R^4, when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5- to 8-membered ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{3e};

or two R^4, when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5- to 8-membered ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s);


R^{3a}, R^{3b}, and R^{3c} are each independently hydrogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{3e}; or

(R^{3a} and R^{3b}), (R^{3b} and R^{3c}), or (R^{3c} and R^{3a}), together with the atom (s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{3e};

R^{3d} and R^{3e} are each independently halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{3f}, -SO_2R^{3f}, -$SO_2NR^{3f}R^{3g}$, -COR^{3f}, -CO_2R^{3f}, -$CONR^{3f}R^{3g}$, -C (=NR^{3f})$NR^{3g}R^{3h}$, -$NR^{3f}R^{3g}$, -$NR^{3f}COR^{3g}$, -$NR^{3f}CONR^{3g}R^{3h}$, -$NR^{3f}CO_2R^{3f}$, -$NR^{3f}SONR^{3f}R^{3g}$, -$NR^{3f}SO_2NR^{3g}R^{3h}$, or –$NR^{3f}SO_2R^{3g}$, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents selected from halogen, -C_{1-8}alkyl, -OR^{3i}, -$NR^{3i}R^{3j}$, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^{3f}, R^{3g}, R^{3h}, R^{3i}, and R^{3j} are each independently hydrogen, -C_{1-8}alkyl, C_{1-8}alkoxy-C_{1-8}alkyl-, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

L^1 is a single bond, alkylene, cycloalkylene, *1-O-alkylene-**1, *1-alkylene-O-**1, *1-NH-alkylene-**1, *1-alkylene-NH-**1, *1-NHC (O)-**1, *1-C (O)NH-**1, alkenylene, or alkynylene; wherein *1 refers to the position attached to Cy1, and **1 refers to the position attached to the pyrrolo[2, 3-b]pyrazine ring;



is a fused heterocyclyl, fused heteroaryl, fused aryl, fused cycloalkyl, fused cycloalkenyl, or fused cycloalkynyl, 

is optionally substituted with R^6;

p is 0, 1, 2, 3, 4; 

is optionally substituted with R^5, m is 0, 1, 2, 3, 4;

R^5 at each of its occurrence, is each independently halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, -C_{1-8}alkyl-cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{5a}, -SO_2R^{5a}, -$SO_2NR^{5a}R^{5b}$, -$POR^{5a}R^{5b}$, -COR^{5a}, -CO_2R^{5a}, -$CONR^{5a}R^{5b}$, -C (=NR^{5a})$NR^{5b}R^{5c}$, -$CH_2CONR^{5a}R^{5b}$, -$CH_2CH_2CONR^{5a}R^{5b}$, -$CH_2CH_2CH_2CONR^{5a}R^{5b}$, -$NR^{5a}R^{5b}$, -$CH_2NR^{5a}R^{5b}$, -$CH_2CH_2NR^{5a}R^{5b}$, -$CH_2CH_2CH_2NR^{5a}R^{5b}$, -$NR^{5a}COR^{5b}$, -$NR^{5a}CONR^{5b}R^{5c}$, -$NR^{5a}CO_2R^{5b}$, -$NR^{5a}SONR^{5b}R^{5c}$, -$NR^{5a}SO_2NR^{5b}R^{5c}$, or -$NR^{5a}SO_2R^{5b}$, each of said -$C_{1-8}$alkyl, -$C_{2-8}$alkenyl, -$C_{2-8}$alkynyl, cycloalkyl, -$C_{1-8}$alkyl-cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{5d}; or two R^5, together with the atoms to which they are attached (provided that the valence theory is met), form a 4-, 5-, 6-, 7- or 8-membered ring, said ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{5e};

R^{5a}, R^{5b} and R^{5c} are each independently hydrogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -C_{1-8}alkyl-C_{1-8}alkoxy, cycloalkyl, -C_{1-8}alkyl-heterocyclyl, -C_{1-8}alkyl-aryl, heterocyclyl, aryl, or heteroaryl, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -C_{1-8}alkyl-C_{1-8}alkoxy, cycloalkyl, -C_{1-8}alkyl-heterocyclyl, -C_{1-8}alkyl-aryl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{5e};

(R^{5a} and R^{5b}), (R^{5b} and R^{5c}), or (R^{5c} and R^{5a}), together with the atom (s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{5e};

R^{5d} and R^{5e} are each independently hydrogen, halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -CF_3, -OR^{5f}, -SO_2R^{5f}, -$SO_2NR^{5f}R^{5g}$, -$POR^{5f}R^{5g}$, -COR^{5f}, -CO_2R^{5f}, -$CONR^{5f}R^{5g}$, -C (=NR^{5h})$NR^{5f}R^{5g}$, -$NR^{5f}R^{5g}$, -$NR^{5f}COR^{5g}$, -$NR^{5h}CONR^{5f}R^{5g}$, -$NR^{5f}CO_2R^{5h}$, -$NR^{5h}SONR^{5f}R^{5g}$, -$NR^{5h}SO_2NR^{5f}R^{5g}$, or –$NR^{5f}SO_2R^{5g}$, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents selected from halogen, -C_{1-8}alkyl, -OR^{5i}, -$NR^{5i}R^{5j}$, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^{5f}, R^{5g}, R^{5h}, R^{5i}, and R^{5j} are each independently hydrogen, oxo, -C_{1-8}alkyl, -C_{1-8}alkoxy, hydroxy, C_{1-8}alkoxy-C_{1-8}alkyl-, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^6 at each of its occurrence, is each independently hydrogen, halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{6a}, -SO_2R^{6a}, -$SO_2NR^{6a}R^{6b}$, -COR^{6a}, -CO_2R^{6a}, -$CONR^{6a}R^{6b}$, -C (=NR^{6a})$NR^{6b}R^{6c}$, -$CH_2CONR^{6a}R^{6b}$, -CH_2 $CH_2CONR^{6a}R^{6b}$, -$CH_2CH_2CH_2CONR^{6a}R^{6b}$, -$NR^{6a}R^{6b}$, -$CH_2NR^{6a}R^{6b}$, -$CH_2$ $CH_2NR^{6a}R^{6b}$, -$CH_2CH_2CH_2NR^{6a}R^{6b}$, -$NR^{6a}COR^{6b}$, -$NR^{6a}CONR^{6b}R^{6c}$, -$NR^{6a}CO_2R^{6b}$, -$NR^{6a}SONR^{6b}R^{6c}$, -$NR^{6a}SO_2NR^{6b}R^{6c}$, or –$NR^{6a}SO_2R^{6b}$, each of said -$C_{1-8}$alkyl, -$C_{2-8}$alkenyl, -$C_{2-8}$alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{6d}; or two R^6, together with the atom to which they are attached (provided that the valence theory is met), form a 4-, 5-, 6-, 7- or 8-membered ring, said ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{6e};


R^{6a}, R^{6b}, and R^{6c} are each independently hydrogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, C_{1-8}alkoxy-C_{1-8}alkyl-, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{6e};

(R^{6a} and R^{6b}), (R^{6b} and R^{6c}), or (R^{6c} and R^{6a}), together with the atom (s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{6e};

R^{6d} and R^{6e} are each independently hydrogen, halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{6f}, -SO_2R^{6f}, -$SO_2NR^{6f}R^{6g}$, -COR^{6f}, -CO_2R^{6f}, -$CONR^{6f}R^{6g}$, -C (=NR^{6h})$NR^{6f}R^{6g}$, -$NR^{6f}R^{6g}$, -$NR^{6f}COR^{6g}$, -$NR^{6h}CONR^{6f}R^{6g}$, -$NR^{6f}CO_2R^{6h}$, -$NR^{6h}SONR^{6f}R^{6g}$, -$NR^{6h}SO_2NR^{6f}R^{6g}$, or –$NR^{6f}SO_2R^{6g}$, each of said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents selected from halogen, -C_{1-8}alkyl, -OR^{6i}, -$NR^{6i}R^{6j}$, cycloalkyl, heterocyclyl, aryl, or heteroaryl;



R^{6f}, R^{6g}, R^{6h}, R^{6i}, and R^{6j} are each independently hydrogen, oxo, -C_{1-8}alkyl, C_{1-8}alkoxy-C_{1-8}alkyl-, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.


2. The compound of claim 1, wherein R^1 and R^2 are each hydrogen or -C_{1-8}alkyl; and/or L^1 is a single bond.







3. The compound of claim 1 or 2, wherein R^3 is –C_{1-8}alkyl, -C_{1-8}alkyl-heterocyclyl or -C_{1-8}alkyl-cycloalkyl, wherein said –C_{1-8}alkyl, -C_{1-8}alkyl-heterocyclyl or -C_{1-8}alkyl-cycloalkyl is optionally substituted with at least one substituents R^{3d}; R^{3d} is independently selected from -C_{1-8}alkyl or -OR^{3f}; R^{3f} is each independently hydrogen, -C_{1-8}alkyl; preferably R^3 is ; or







R^3 is -$CONR^{3a}R^{3b}$; R^{3a} and R^{3b} are each independently hydrogen or -C_{1-8}alkyl; each of said -C_{1-8}alkyl is substituted with at least one substituents selected from hydrogen, -OR^{3f}, CN, 3- to-7 membered heterocyclyl comprising 1 or 2 heteroatoms selected from nitrogen, oxygen; R^{3f} is selected from hydrogen or -C_{1-8}alkyl; or







R^3 is -$CONR^{3a}R^{3b}$ or -$NR^{3a}R^{3b}$; R^{3a} and R^{3b} together with the nitrogen atom to which they are attached is 4- to 12-membered ring comprising 1 or 2 additional nitrogen or oxygen heteroatoms as ring, said ring is optionally substituted with at least one substituents R^{3e}; R^{3e} each is selected from oxo, -C_{1-8}alkyl, -OR^{3f}, -$NR^{3f}R^{3g}$, said-C_{1-8}alkyl is optionally substituted by at least one halogen, wherein R^{3f} and R^{3g} are each independently hydrogen, or -C_{1-8}alkyl; or





R^3 is selected from  or .

4. The compound of any one of claims 1-3, wherein R^3 is selected from 

( or ),, , , , , ( or

), , , , ( or ),

, , , , ( or ),

 ( or ) or .











5. The compound of any one of claims 1-4, wherein n is 0, 1 or 2; R^4 is selected from halogen, -C_{1-8}alkyl (preferably methyl), halogen, CN, -OR^{3a} or -$NR^{3a}CONR^{3b}R^{3c}$; said -C_{1-8}alkyl is optionally substituted with at least one substituents R^{3d}; R^{3a}, R^{3b} and R^{3c} are each









independently hydrogen, -C_{1-8}alkyl (preferably methyl); R^{3d} is each independently halogen or -C_{1-8}alkyl.


6. The compound of claim 5, wherein n is 1, R^4 is selected from -C_{1-8}alkyl, halogen, CN, OR^{3a} or -$NR^{3a}CONR^{3b}R^{3c}$; said -C_{1-8}alkyl is optionally substituted with at least one substituents R^{3d}; R^{3a}, R^{3b} and R^{3c} are each independently hydrogen, or -C_{1-8}alkyl (preferably methyl); R^{3d} is each independently halogen or -C_{1-8}alkyl; or

n is 2, and R^4 is halogen; or



n is 1 or 2, and R^4 is selected from methyl, F, OH, CN, -CHF_2 or -$NHCOCH_3$;or



n is 0, and R^3 is selected from , , , , , , , , , or ;or .



7. The compound of any one of claims 1-6, wherein n is 1, and R^3 is selected from , , , , , , , or ; and R^4 is methyl, F, OH, CN, -CHF_2 or -$NHCOCH_3$; or

n is 2, and R^3 is selected from , and R^4 is F.

8. The compound of any one of claims 1-2, wherein R^3 and R^4, when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5- to 8-membered ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{3e}; each R^{3e} is independently selected from -C_{1-8}alkyl or oxo.


9. The compound of claim 8, wherein  is , X=NH or O, and R^{3e} is -C_{1-8}alkyl; or

wherein  is ; and n=2, two R^4, when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a




5-membered ring comprising 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s); wherein  is  or .




10. The compound of any one of claims 1-9, wherein is benzo fused heterocyclyl, benzo fused heteroaryl, benzo fused cycloalkyl, benzo fused cycloalkenyl, benzo fused cycloalkynyl;

wherein the benzo fused heterocyclyl is indolinyl, isoindolinyl, benzopyranyl, dihydrothiazolopyrimidinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzofuranyl, dihydrobenzoxazinyl, dihydrobenzoimidazolyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, benzodioxolyl, benzodioxonyl, chromanyl, chromenyl, octahydrochromenyl, dihydrobenzodioxynyl, dihydrobenzoxezinyl, dihydrobenzodioxepinyl, dihydrothienodioxynyl, dihydrobenzooxazepinyl, tetrahydrobenzooxazepinyl, dihydrobenzoazepinyl, tetrahydrobenzoazepinyl, isochromanyl, or chromanyl;and/or the benzo fused heteroaryl is benzisoxazolyl, benzodiazolyl, benzofuranyl, benzofurazanyl, benzofuryl, benzoimidazolyl, benzoisothiazolyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzothiophenyl, benzotriazolyl, benzoxadiazolyl, benzoxazolyl, indazolyl, indolyl, isobenzofuryl, isoindolyl, isoquinolinyl (or isoquinolyl), phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinolinyl (or quinolyl), or quinoxalinyl; in some examples, indazolyl is e.g., 1H-indazol-4-yl, 2H-indazol-4-yl, 1H-indazol-5-yl, 2H-indazol-5-yl, 1H-indazol-7-yl; benzodiazolyl is e.g., 1H-benzo[d]imidazol-4-yl, 1H-1, 3-benzodiazol-5-yl or 1H-benzo[d]imidazol-5-yl, 1H-benzo[d]imidazol-4-yl, 1H-benzo[d]imidazol-6-yl; benzooxazolyl is e.g., benzo[d]oxazol-6-yl; benzooxadiazolyl is e.g., benzo[c][1, 2, 5]oxadiazol-4-yl; or




wherein  is a bicyclic fused heteroaryl selected from furopyridinyl, furopyrrolyl, imidazopyridinyl, imidazopyridyl, imidazothiazolyl, indolizinyl, naphthyridinyl, pyrazinopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridyl, pyrazolotriazinyl, pyridazolopyridyl, pyrrolopyridinyl, thiazolopyridyl, thienopyrazinyl, thienopyrazolyl, thienopyridyl, thienopyrrolyl, thienothienyl, or triazolopyridyl; in some example, imidazopyridinyl is e.g., imidazo[1, 2-a]pyridin-5-yl or imidazo[1, 5-a]pyridin-5-yl.

11. The compound of claim 10, wherein tetrahydroisoquinolinyl is selected from 1, 2, 3, 4-tetrahydroisoquinolinyl, 1, 2, 3, 4-tetrahydroisoquinolin-6-yl or 1, 2, 3, 4-tetrahydroisoquinolin-7-yl; tetrahydrobenzooxazepinyl is selected from 2, 3, 4, 5-tetrahydrobenzooxazepinyl, 2, 3, 4, 5-tetrahydrobenzo[f][1, 4]oxazepin-8-yl, or 2, 3, 4, 5-tetrahydrobenzo[f][1, 4]oxazepin-7-yl; tetrahydrobenzoazepinyl is selected from 2, 3, 4, 5-tetrahydrobenzoazepinyl, 2, 3, 4, 5-tetrahydro-1H-benzo[c]azepin-7-yl and 2, 3, 4, 5-tetrahydro-1H-benzo[d]azepin-7-yl; isoindolinyl is selected from isoindolin-5-yl; isochromanyl is selected from isochroman-5-yl; dihydroisobenzofuranyl is selected from 1, 3-dihydroisobenzofuran-4-yl.

12. The compound of claim 10, wherein  is  or , p=0, 1, 2 or 3; m=0, 1, 2, 3 or 4; R^6 and R^5 are defined for Formula (I).

13. The compound of any one of claims 10-12, wherein  is  or , m=1, 2, 3 or 4;

each R^5 is independently selected from -C_{1-8}alkyl, -C_{1-8}alkyl-cycloalkyl, heterocyclyl or heteroaryl -$CONR^{3a}R^{3b}$, $CH_2CONR^{5a}R^{5b}$, -CH_2 $CH_2CONR^{5a}R^{5b}$, -$NR^{5a}R^{5b}$, -$CH_2NR^{5a}R^{5b}$, -CH_2 $CH_2NR^{5a}R^{5b}$, said -C_{1-8}alkyl, -C_{1-8}alkyl-cycloalkyl or heterocyclyl or heteroaryl is optionally substituted with at least one R^{5d}, and R^{5a}, R^{5b} and R^{5d} are defined for Formula (I); wherein R^6 is selected from -C_{1-8}alkyl, -OR^{6a} or -$NR^{6a}R^{6b,}$ said -C_{1-8}alkyl is optionally substituted with at least one substituents R^{6d}, R^{6a} and R^{6b} are each hydrogen or -C_{1-8}alkyl; R^{6d} is each independently hydrogen, halogen or -C_{1-8}alkyl.


14. The compound of any one of claims 10-12, wherein  is selected from  or , R^5 is selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 1-methylpropyl or t-butyl; .R^6 is selected from -CH_3, -OCH_3, -$NHCH_3$, -CHF_2, or -C $(CH_3)_2OH$.

15. The compound of any one of claims 12-13, wherein R^5 is selected from methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 1-methylpropyl or t-butyl, -C_{1-8}alkyl-cycloalkyl, heterocyclyl or heteroaryl, said -C_{1-8}alkyl, -C_{1-8}alkyl-cycloalkyl, heteroaryl or heterocyclyl is optionally substituted with at least one substituents R^{5d}; R^{5d} is selected from -C_{1-8}alkyl, -OR^{5f}, -$NR^{5f}R^{5g}$, -CO_2R^{5f}, heteroaryl, heterocyclyl, -SO_2R^{5f}, -$POR^{5f}R^{5g}$, -$CONR^{5f}R^{5g}$, oxo or -CF_3; R^{5f} and R^{5g} are each independently hydrogen, -C_{1-8}alkyl, -C_{1-8}alkoxy or hydroxy; or






R^5 is -$NR^{5a}R^{5b}$, -$CH_2NR^{5a}R^{5b}$, -CH_2 $CH_2NR^{5a}R^{5b}$; R^{5a} and R^{5b} together with the nitrogen atom to which they are attached form a 4- to 7- membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen, said ring is optionally

substituted with at least one substituents R^{5e}; R^{5e} is each independently selected from C_{1-8}alkyl, OR^{5f}; R^{5f} is each independently selected from hydrogen or -C_{1-8}alkyl; or




































R^5 is selected from -$CONR^{5a}R^{5b}$, -$CH_2CONR^{5a}R^{5b}$, -$CH_2CH_2CONR^{5a}R^{5b}$, wherein R^{5a} is hydrogen, methyl, ethyl; R^{5b} is selected from -C_{1-8}alkyl, cycloalkyl, -C_{1-8}alkyl-heterocyclyl, -C_{1-8}alkyl-aryl, heterocyclyl, aryl, said -C_{1-8}alkyl, cycloalkyl, -C_{1-8}alkyl-heterocyclyl, -C_{1-8}alkyl-aryl, heterocyclyl, aryl is optionally substituted with at least one substituents R^{5e}, R^{5e} is selected from halogen, -CH_2OH or OR^{5f}, R^{5f} is selected from hydrogen, cycloalkyl or -C_{1-8}alkyl.




16. The compound of claim 15, wherein, R^5 is methyl, ethyl, propyl, butyl, pentyl or hexyl, -CH_2OH, -C_2H_4OH, $C_2H_4NHCH_3$, -$C_2H_4OCH_3$, .




17. The compound of claim 15, wherein R^5 is -$CONR^{3a}R^{3b}$, $CH_2CONR^{5a}R^{5b}$ or -CH_2 $CH_2CONR^{5a}R^{5b}$, R^{5a} is hydrogen or methyl; and R^{5b} is selected from cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups.




18. The compound of claim 17, wherein R^5 is $-CONR^{5a}R^{5b}$, $CH_2CONR^{5a}R^{5b}$ or $-CH_2CH_2CONR^{5a}R^{5b}$, R^{5a} is hydrogen or methyl; and R^{5b} is heterocyclyl selected from , , , , ) or phenyl, said heterocyclyl or phenyl is optionally substituted with at least one substituents R^{5e} selected from halogen, $-C_{1-8}$alkyl or $-OR^{5f}$; R^{5f} is each independently hydrogen or $-C_{1-8}$alkyl; or

R^5 is selected from $-CONR^{5a}R^{5b}$, $CH_2CONR^{5a}R^{5b}$, $-CH_2CH_2CONR^{5a}R^{5b}$, wherein R^{5a} and R^{5b} together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{5e}; R^{5e} is each independently halogen, $-C_{1-8}$alkyl, $-OR^{5f}$, R^{5f} is each independently hydrogen or $-C_{1-8}$alkyl.




19. The compound of any one of claims 1-18, wherein R^5 is selected from methyl, ethyl, propyl, butyl, pentyl or hexyl, $-CH_2OH$, $-C_2H_4OH$, $C_2H_4NHCH_3$, $-C_2H_4OCH_3$, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , .






















20. The compound of claim 13, wherein  is  or , m=2, 3 or 4, R^5 is each independently halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, -C_{1-8}alkyl-cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{5a}, -SO_2R^{5a}, -$SO_2NR^{5a}R^{5b}$, -$POR^{5a}R^{5b}$, -COR^{5a}, -CO_2R^{5a}, -$CONR^{5a}R^{5b}$, -C ($=NR^{5a}$)$NR^{5b}R^{5c}$, -$CH_2CONR^{5a}R^{5b}$, -$CH_2CH_2CONR^{5a}R^{5b}$, -$CH_2CH_2CH_2CONR^{5a}R^{5b}$, -$NR^{5a}R^{5b}$, -$CH_2NR^{5a}R^{5b}$, -$CH_2CH_2NR^{5a}R^{5b}$, -$CH_2CH_2CH_2NR^{5a}R^{5b}$, -$NR^{5a}COR^{5b}$, -$NR^{5a}CONR^{5b}R^{5c}$, -$NR^{5a}CO_2R^{5b}$, -$NR^{5a}SONR^{5b}R^{5c}$, -$NR^{5a}SO_2NR^{5b}R^{5c}$, or -$NR^{5a}SO_2R^{5b}$, each of said -$C_{1-8}$alkyl, -$C_{2-8}$alkenyl, -$C_{2-8}$alkynyl, cycloalkyl, -$C_{1-8}$alkyl-cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{5d}; R^6, R^{5a}, R^{5b}, R^{5c} and R^{5d} are defined for Formula (I).

























21. The compound of claim 20, wherein  is  or , m=2, R^5 is each independently -C_{1-8}alkyl or -$CONR^{5a}R^{5b}$, R^{5b} and R^{5d} are hydrogen or -C_{1-8}alkyl; R^6 is selected from -C_{1-8}alkyl, -OR^{6a} or -$NR^{6a}R^{6b}$, said -C_{1-8}alkyl is optionally substituted with at least one substituents R^{6d}, R^{6a} and R^{6b} are each hydrogen or -C_{1-8}alkyl; R^{6d} is each independently hydrogen, halogen or -C_{1-8}alkyl.






















22. The compound of claim 21, wherein  is  or ; R^6 is selected from -CH_3, -OCH_3, -$NHCH_3$, -CHF_2, or -C (CH_3)$_2$OH.






















23. The compound of claim 1, selected from:






















		
1	2	3



















		
4	5	6
		
7A	7B	8
		
9	10	11
		
12	13	14
		
15	16	17
		
18	19	20
		
21	22	23

		
24	25	26
		
27	28	29
		
30	31	32
		
33	34	35
		
36	37	38
		
39	40	41
		
42	43	44
		
45	46	47

		
48	49	50
		
51	52	53
		
54	55	56
		
57	58	59
		
60	61	62
		
63	64	65
		
66	67	68

		
69	70	71
		
72	73	74
		
75	76	77
		
78	79	80
		
81	82	83
		
84	85	86
		
87	88	89

		
90	91	92
		
93	94	95
		
96	97	98
		
99	100	101
		
102	103	104
		
105	106	107
		
108	109	110

		
111	112	113
		
114	115	116
		
117	118	119
		
120	121	122
		
123	124	125
		
126	127	128

24. A pharmaceutical composition comprising the compound of any one of claims 1-23 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

25. A use of the compound of any one of claims 1-23 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in treating cancer.